J

Jazz Pharmaceuticals

Biopharmaceuticals focused on neuroscience and oncology

Process Technician Senior Coordinator

Full-TimeUpdated
No salary listed
Mid, Senior
United Kingdom
In Person
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • Experience gained in a regulated production environment, ideally within the pharmaceutical, chemical, or food industry.
  • Ideally hold qualifications gained in the pharmaceutical industry, such as NVQs or similar.
  • Proven experience of team supervision or leadership in the pharmaceutical or a related industry.
  • Maintain applicable cGxP and environment, health, and safety (EH&S) knowledge.
  • Carry out work in a way that protects health, safety, security, and the environment, and report shortcomings in company arrangements.
  • Responsible for Botanical Drug Product (BDP) manufacturing and packaging processes in accordance with current Good Manufacturing Practice (cGMP) standards, as both initiator and checker.
  • Record manufacturing and process conditions in batch documentation and equipment/area logbooks.
  • Complete area and equipment cleaning procedures to cGMP standards.
  • Comply with cGMP and EH&S standards in relevant standard operating procedures (SOPs) and working practices.
  • Author and update batch documentation, SOPs, and associated forms.
  • Complete quality-related documentation, including deviations, corrective and preventive actions (CAPAs), protocols, and change controls.
  • Be flexible with working hours and available to complete a production process if it overruns.
  • Inform department management immediately of atypical events or deviations.
  • Potentially act as the BDP department EH&S representative and undertake the associated tasks.
  • Potentially take responsibility for ordering consumables and critical-to-quality items.
  • Ensure activities under their control minimize risks to health, safety, security, and the environment.
  • Demonstrate good numeracy and written communication skills.
  • Have a good working knowledge of standard Microsoft packages, including Excel and Word.
  • Maintain positive working relationships with internal and external stakeholder groups.
  • Look for areas of improvement and share ideas and information.
  • Assist colleagues as required.
Responsibilities
  • Ensure delivery against the schedule for all BDP production batches.
  • Ensure all BDP batch documentation is processed in accordance with cGMP and current procedures.
  • Perform routine microbiological testing in the Commercial Manufacturing Suite (CMS).
  • Liaise with supply chain, warehouse, engineering, quality control (QC), and quality assurance (QA) on BDP production scheduling.
  • Train other technicians on new processes and changes to manufacturing techniques.
  • Identify and implement improvements across BDP production processes and working practices where applicable.
  • Complete additional tasks assigned by production management outside the core duties.
  • Train and coach new starters and retrain individuals in BDP manufacturing and packaging processes.
  • Improve efficiency and reduce costs across BDP manufacturing and packaging processes.
  • Execute additional tasks to meet department objectives.
  • Where applicable, manage individual and team performance.
Desired Qualifications
  • The role holder ideally has qualifications gained in the pharmaceutical industry, such as NVQs or similar.
  • The role holder ideally has experience in a regulated production environment, preferably in the pharmaceutical, chemical, or food industry.

About the company

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $1.21 billion; Jazz raised full-year guidance to $4.68 billion.
  • Actio's ABS-1230 adds first-in-class KCNT1 epilepsy upside after the September 15, 2026 close.
  • Oncology revenue exceeded $1 billion in 2025, driven by Zepzelca and Ziihera.

What critics are saying

  • Xywav faces Lupin, Teva, and Tris patent fights; generic entry threatens 2027 cash flow.
  • Xywav and EPIDIOLEX still dominate value; one patent loss or safety issue would crush earnings.
  • Jazz paid $820 million for Actio before registrational proof; ABS-1230 can still fail.

What makes Jazz Pharmaceuticals unique

  • Ziihera launched August 2026, targeting $3B-$5B across HER2-positive tumors.
  • EPIDIOLEX holds exclusivity into the late 2030s and now funds four new trials.
  • Xywav's low-sodium oxybate formulation keeps narcolepsy patients despite generic Xyrem pressure.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Paid Vacation

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 16th, 2026
Jazz wins FDA approval for Ziihera as commercial chief Pearce plans to retire; 2026 guidance $4.6B+

Jazz Pharmaceuticals has won US Food and Drug Administration (FDA) approval for its cancer drug Ziihera. The approval raised the drug's projected peak sales range. Separately, chief commercial officer Samantha Pearce plans to retire by June 30, 2027, or when a successor is appointed. Jazz has started an internal and external search. In its second-quarter 2026 update, Jazz reported revenue of $1,208.3 million and raised full-year 2026 guidance to $4.60–4.75 billion. The share price still fell 7.6% after earnings. Simply Wall St's narrative projects revenue of $5.7 billion and earnings of $1.7 billion by 2029, implying a fair value of $294.27 a share.

Yahoo Finance
Sep 20th, 2026
Jazz Pharma raises zanidatamab peak sales target to $3B-$5B as oncology revenue hits $1B

Jazz Pharmaceuticals reported its oncology revenue surpassed $1 billion in 2025, marking a 32% year-over-year increase. The growth follows three recent product launches, including zanidatamab, Modeyso and Zepzelca's FORTE regimen. The company raised zanidatamab's estimated peak-sales opportunity to $3 billion-$5 billion. Jazz aims to increase HER2-directed treatment adoption in gastroesophageal cancer, where only 60% of eligible HER2-positive patients currently receive such therapy. Jazz estimates the US incidence of HER2-positive gastroesophageal adenocarcinoma at approximately 8,000 patients, with a labelled population of 3,000 to 4,000 patients. The company is also developing zanidatamab for biliary tract cancer, colorectal cancer, non-small cell lung cancer and breast cancer. Jazz maintains commercial investment whilst preserving financial flexibility for acquisitions across oncology, epilepsy and sleep disorders.

Yahoo Finance
Sep 11th, 2026
Jazz Pharmaceuticals stock climbs 29.7% but analysts warn of declining margins and weak returns

Jazz Pharmaceuticals' stock has risen 29.7% over the past six months, outpacing the S&P 500 by 17 percentage points to reach $240.49 per share. However, analysts point to concerning trends in the company's fundamentals. The company's adjusted operating margin has declined by 2.6 percentage points over five years, despite revenue growth that should have improved economies of scale. Its trailing 12-month adjusted operating margin stood at 41.7%. Additionally, Jazz Pharmaceuticals' five-year average return on invested capital was just 2.7%, below the typical cost of capital for healthcare companies. This suggests mediocre efficiency in deploying capital for growth. The stock currently trades at 9.6× forward price-to-earnings ratio. Analysts consider this valuation reasonable but believe the company's weakening fundamentals present downside risk.

StockTitan
Aug 27th, 2026
Jazz Pharmaceuticals prices upsized $1.1B exchangeable notes offering with $225M share repurchase

Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.

Yahoo Finance
Aug 26th, 2026
Jazz Pharmaceuticals launches Ziihera for HER2-positive cancer with $3B–$5B peak sales outlook

Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.